WBDE(SZ:002082) Ge Long Hui A P P·2025-12-12 13:24Core Viewpoint - Wanbangde (002082.SZ) announced the completion of enrollment for 50 subjects in the key Phase II/III clinical trial of its new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease dementia [1] Group 1: Company Developments - Wanbangde's wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., is conducting the clinical trial for Huperzine A, which is classified as a Class 2 new drug [1] - The drug is a cholinesterase inhibitor designed to improve cognitive function and has shown potential in preclinical studies to delay the progression of Alzheimer's disease [1] Group 2: Drug Characteristics and Potential - Huperzine A exhibits a range of benefits, including the reduction of beta-amyloid protein, anti-inflammatory effects, antioxidant stress response, and neuroprotection [1] - The drug is expected to become a broad-spectrum treatment for Alzheimer's disease dementia [1]